文献速递头颈与中枢神经肿瘤

贝伐珠单抗联合放化疗治疗儿童新诊断高级别胶质瘤的II期随机试验(HERBY)

Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
PubMed 文献 · J Clin Oncol · 2018-02-07

结论:加用贝伐珠单抗未改善无事件生存期。

要点

  • 贝伐珠单抗联合放疗+替莫唑胺未显著改善儿童新诊断高级别胶质瘤的无事件生存期。
  • 联合组严重不良事件发生率为58%,高于对照组的48%。
  • 联合组因不良事件中断治疗的比例为22%,高于对照组的5%。

核心结论

  • 在儿童新诊断高级别胶质瘤中,放疗+替莫唑胺基础上加用贝伐珠单抗未改善无事件生存期。

研究设计与样本

  • 患者随机接受放疗+替莫唑胺(n=59)或贝伐珠单抗联合放疗+替莫唑胺(n=62)。

主要发现

  • 总生存分析中,加用贝伐珠单抗未降低死亡风险(HR 1.23,95%CI 0.72-2.09)。
  • 联合组发生至少一项严重不良事件的患者为35例(58%),对照组为27例(48%)。
  • 联合组因不良事件中断研究治疗的患者为13例(22%),对照组为3例(5%)。

关键数值与推荐

  • 放疗:1.8 Gy,每周5天;替莫唑胺:75 mg/m2/天,共6周;休息4周后,最多12个28天周期的替莫唑胺(第1周期:150 mg/m2/天,第1-5天;第2-12周期:200 mg/m2/天,第1-5天)。
  • 贝伐珠单抗:10 mg/kg,每2周一次。

临床怎么用

  • 不推荐在儿童新诊断高级别胶质瘤的放疗+替莫唑胺方案中常规加用贝伐珠单抗。
  • 临床决策时应权衡加用贝伐珠单抗带来的严重不良事件和治疗中断风险。

局限性

  • 结果与既往成人试验不可比,凸显儿童特异性研究的重要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (HGG). Methods The randomized, parallel group, multicenter, open-label HERBY trial ( ClinicalTrials.gov identifier: NCT01390948) enrolled patients age ≥ 3 years to ≤ 18 years with localized, centrally neuropathology-confirmed, nonbrainstem HGG. Eligible patients were randomly assigned to receive RT + TMZ (RT: 1.8 Gy, 5 days per week, and TMZ: 75 mg/m2 per day for 6 weeks; 4-week treatment break; then up to 12 × 28-day cycles of TMZ [cycle 1: 150 mg/m2 per day, days 1 to 5; cycles 2 to 12: 200 mg/m2 per day, days 1 to 5]) with or without BEV (10 mg/kg every 2 weeks). The primary end point was event-free survival (EFS) as assessed by a central radiology review committee that was blinded to treatment. We report findings of EFS at 12 months after the enrollment of the last patient. Results One hundred twenty-one patients were enrolled (RT+TMZ [n = 59]; BEV plus RT+TMZ [n = 62]). Central radiology review committee-assessed median EFS did not differ significantly between treatment groups (RT+TMZ, 11.8 months; 95% CI, 7.9 to 16.4 months; BEV plus RT+TMZ, 8.2 months; 95% CI, 7.8 to 12.7 months; hazard ratio, 1.44; P = .13 [stratified log-rank test]). In the overall survival analysis, the addition of BEV did not reduce the risk of death (hazard ratio, 1.23; 95% CI, 0.72 to 2.09). More patients in the BEV plus RT+TMZ group versus the RT+TMZ group experienced one or more serious adverse events (n = 35 [58%] v n = 27 [48%]), and more patients who received BEV discontinued study treatment as a result of adverse events (n = 13 [22%] v n = 3 [5%]). Conclusion Adding BEV to RT+TMZ did not improve EFS in pediatric patients with newly diagnosed HGG. Our findings were not comparable to those of previous adult trials, which highlights the importance of performing pediatric-specific studies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Grill J, Massimino M, Bouffet E, et al. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. J Clin Oncol. 2018. PMID: 29412784. doi:10.1200/JCO.2017.76.0611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。